Patent US5208221A successfully refreshed from Google Patents.
US5208221A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
Assignee: Stichting Rega VZW
•
Filing: 1990-11-29
•
Granted: 1993-05-04
•
Expires: 2010-11-29
Abstract
Abstract The present invention concerns nucleotide analogs and their compositions and use. In particular it relates to novel (phosphonomethoxy) methoxy purine/pyrimidine derivatives.
Inventors
- 👤 Choung U. Kim
- 👤 John C. Martin
- 👤 Bing Y. Luh
- 👤 Peter F. Misco
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 09:08
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/547; C07F9/6561; C07F9/65616; A; A61; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; C07F9/28; C07F9/38; C07F9/40; C07F9/4003; C07F9/4006; C07F9/645; C07F9/6509; C07F9/6512
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
47 words
A compound of the formula ##STR34## wherein R is hydrogen, alkyl having 1 to 6 carbon atoms, hydroxyalkyl with 1 to 6 carbon atoms, or haloalkyl having 1 to 6 carbon atoms; and B is a purine base or pyrimidine base or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
47 words
A compound of the formula ##STR34## wherein R is hydrogen, alkyl having 1 to 6 carbon atoms, hydroxyalkyl with 1 to 6 carbon atoms, or haloalkyl having 1 to 6 carbon atoms; and B is a purine base or pyrimidine base or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
33 words
The compound of claim 1 wherein the purine base is selected from the group consisting of 2-aminopurine, 2,6-diaminopurine; xanthine, hypoxanthine; guanine, 8-bromoguanine, 8-chloroguanide, 8-aminoguanine, 8-hydrozinoguanine, 8-hydroxyguanine, 8-methylguanine, 8-thioguanine and 3-deazaguanine; adenine and deazaadenine.
Claim 4
Dependent Claim
29 words
The compound of claim 1 wherein the pyrimidine base selected from the group consisting of cytosine, 5-ethylcytosine and 5-methylcytosine; thymine; pyrimidine; uracil, 5-chlorouracil, 5-bromouracil, 5-ethyluracil, 5-iodouracil, 5-propyluracil and 5-vinyluracil.
Claim 5
Dependent Claim
11 words
The pharmaceutically acceptable salt of claim 1 which is ammonium salt.
Claim 6
Dependent Claim
11 words
The compound of claim 2 wherein the purine base is adenine.
Claim 7
Dependent Claim
17 words
The compound of claim 2 wherein the purine base is deazadenine, or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
11 words
The compound of claim 2 wherein the purine base is guanine.
Claim 9
Dependent Claim
28 words
The compound of claim 2 wherein the purine base is a guanine derivative selected from the group consisting of 8-bromoguanine, 8-chloroguanide, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, 8-methylguanine, 8-thioguanine and 3-deazaguanine.
Claim 10
Dependent Claim
8 words
The compound of claim 1 which is 9-[(phosphonomethoxy)methoxy]adenine.
Claim 11
Dependent Claim
8 words
The compound of claim 1 which is 9-[(phosphonomethoxy)methoxy]guanine.
Claim 12
Dependent Claim
8 words
The compound of claim 1 which is 9-[2-hydroxy-2-(phosphonomethoxy)ethoxy]adenine.
Claim 13
Dependent Claim
34 words
The intermediate having the formula ##STR35## wherein R is alkyl C 1-4 , or aryl; X is I, or OAc; and B is as defined in claim 1, or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
47 words
A method for treating a warm blooded animal infected with herpes simplex virus I, herpes simplex virus II, or human cytomegalovirus, which comprises administering to said warm blooded animal an effective amount of at least one compound of claim 1, or a salt, hydrate or solvate thereof.
Claim 15
Dependent Claim
39 words
A method for treating a warm blooded animal infected with murine leukemia virus, which comprises administering to said warm blooded animal an effective amount of at least one compound of claim 1, or a salt, hydrate or solvate thereof.
Claim 16
Dependent Claim
29 words
A pharmaceutical composition containing an effective amount of at least one compound of claim 1, or a salt, hydrate or solvate thereof, in combination with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4868187A
Cited
WO1984000737A1
Cited
GB2134907A
Cited
WO1984004748A1
Cited
US4808716A
Cited
WO1987003446A1
Cited
EP0253412B1
Cited
EP0269947B1
Cited
WO1988005438A1
Cited
WO1989000255A1
Cited
EP0319228A2
Cited
US4988680A
Cited
WO1989010923A1
Cited
US4952707A
Cited
EP0353955A2
Cited
US5055458A
Cited
US4988703A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-03 | 1996-11-02 | 1997-05-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-03 | 2000-11-02 | 2001-05-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-03 | 2004-11-02 | 2005-05-04 | $7700.00 | Window Closed / Lapsed |